[Effectiveness and tolerance of digitaloid treatment in cardiac insufficiency].
Ever since digitaloids have been used in the treatment of cardiac failure, their effectiveness in cases with sinus rhythm has been controversial. Nevertheless, their inotropic effect at therapeutic concentrations has been well demonstrated in man. The haemodynamic benefit in cardiac failure is greater the more severe the condition. Recent studies have shown that the patients who respond best to digitaloid treatment are those with chronic severe heart failure with ventricular dilatation, reduction in the ejection fraction and a gallop on auscultation. In contrast, when digitaloid treatment is suspended in patients with functional class II or III ischaemic heart failure, there does not appear to be any aggravation provided diuretic and/or vasodilator treatment is continued.
D000251:Adenosine Triphosphatases / Q000037:antagonists & inhibitors; D004071:Digitalis Glycosides / Q000494:pharmacology / Q000627:therapeutic use*; D004361:Drug Tolerance; D006333:Heart Failure / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D009200:Myocardial Contraction / Q000187:drug effects; D013268:Stimulation, Chemical; D013318:Stroke Volume / Q000187:drug effects
D004071:Digitalis Glycosides; D000251:Adenosine Triphosphatases
Efficacitè et tolèrance du traitement digitalique dans l'insuffisance cardiaque.